Claude Stowell - Benchmark Botanics Chief Potanicals
Insider
Claude Stowell is Chief Potanicals of Benchmark Botanics
| Age | 69 |
| Phone | 604 238 0005 |
| Web | https://www.craftportcannabis.com |
Benchmark Botanics Management Efficiency
The company has return on total asset (ROA) of (0.2084) % which means that it has lost $0.2084 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (11.5638) %, meaning that it generated substantial loss on money invested by shareholders. Benchmark Botanics' management efficiency ratios could be used to measure how well Benchmark Botanics manages its routine affairs as well as how well it operates its assets and liabilities.Benchmark Botanics has accumulated 8.08 M in total debt with debt to equity ratio (D/E) of 1.5, which is about average as compared to similar companies. Benchmark Botanics has a current ratio of 0.13, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Benchmark Botanics until it has trouble settling it off, either with new capital or with free cash flow. So, Benchmark Botanics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Benchmark Botanics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Benchmark to invest in growth at high rates of return. When we think about Benchmark Botanics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael BSc | Avant Brands | 40 | |
| Eugene III | Biofrontera | 40 | |
| Chris Pearson | Avant Brands | N/A | |
| Kevin MacDermott | cbdMD Inc | 62 | |
| Sandra Beaver | Evolus Inc | 47 | |
| Sibyl Swift | cbdMD Inc | 44 | |
| Kyle Marko | Avant Brands | N/A | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| CMA CPA | Avant Brands | 47 | |
| Matthew Whitt | Avant Brands | N/A | |
| David Erickson | Evolus Inc | N/A | |
| David Lynn | Avant Brands | N/A | |
| Thomas Flow | Akanda Corp | 46 | |
| Raymond Coffman | cbdMD Inc | 62 | |
| Hermann Lubbert | Biofrontera | 68 | |
| John Weston | cbdMD Inc | N/A | |
| Tejinder Virk | Akanda Corp | 42 | |
| Matthew Coapman | cbdMD Inc | 48 | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Erica CPA | Biofrontera | 39 | |
| David Buckle | Avant Brands | N/A | |
Management Performance
| Return On Equity | -11.56 | |||
| Return On Asset | -0.21 |
Benchmark Botanics Leadership Team
Elected by the shareholders, the Benchmark Botanics' board of directors comprises two types of representatives: Benchmark Botanics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Benchmark. The board's role is to monitor Benchmark Botanics' management team and ensure that shareholders' interests are well served. Benchmark Botanics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Benchmark Botanics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Claude Stowell, Chief Potanicals | ||
| CPA CGA, Co Controller | ||
| Feng Lu, CEO CFO | ||
| Yuan Gao, Corp Director | ||
| Dennis Ling, Managing Market |
Benchmark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Benchmark Botanics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -11.56 | |||
| Return On Asset | -0.21 | |||
| Operating Margin | (18.13) % | |||
| Current Valuation | 6.45 M | |||
| Shares Outstanding | 58.99 M | |||
| Price To Book | 0.88 X | |||
| Price To Sales | 4.61 X | |||
| Revenue | 1.01 M | |||
| Gross Profit | (62.33 K) | |||
| EBITDA | (12.61 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Benchmark Pink Sheet
Benchmark Botanics financial ratios help investors to determine whether Benchmark Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Benchmark with respect to the benefits of owning Benchmark Botanics security.